HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models.
Journal of Clinical Investigation, 2020 The Warburg effect is a tumor related phenomenon that may be targeted therapeutically. Here, we showed that glioblastoma cultures and patient tumors harbored super-enhancers in several genes related to the Warburg effect.
T. Nguyen +18 more
semanticscholar +1 more source
Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer [PDF]
, 2019 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel ...
Adile, Ashley A. +19 more
core +3 more sources
Archives of Pharmaceutical Sciences Ain Shams University, 2018 Despite the increased success rates of histone deacetylases inhibitors (HDACi) as potent anticancer agents, many metabolic obstacles face the hydroxamic acid-based HDAC inhibitors, which inspired us to develop non-hydroxamate HDAC inhibitors.
Heba M. Hesham +2 more
doaj +1 more source
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer [PDF]
, 2016 Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer ...
A Hayashi +130 more
core +1 more source
Rational Combinations Using HDAC Inhibitors [PDF]
Clinical Cancer Research, 2009 Abstract In addition to well-characterized genetic abnormalities that lead to cancer onset and progression, it is now recognized that alterations to the epigenome may also play a significant role in oncogenesis. As a result, epigenetic-modulating agents such as histone deacetylase inhibitors (HDACi) have attracted enormous attention as ...
Bots, Michael, Johnstone, Ricky W.
openaire +2 more sources
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Molecules, 2015 Histone dacetylases (HDACs) are a group of enzymes that remove acetyl groups from histones and regulate expression of tumor suppressor genes. They are implicated in many human diseases, especially cancer, making them a promising therapeutic target for ...
Madhusoodanan Mottamal +3 more
doaj +1 more source
Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
Frontiers in Oncology, 2021 We have extended our analyses of HDAC inhibitor biology in sarcoma. The multi-kinase inhibitor axitinib interacted with multiple HDAC inhibitors to kill sarcoma cells.
Jane L. Roberts +3 more
doaj +1 more source
Turning off the switch in medulloblastoma. The inhibitory acetylation of an oncogene [PDF]
, 2010 [No abstract ...
CANETTIERI, Gianluca +4 more
core +1 more source
Frontiers in Immunology, 2023 Breast cancer is one of the common malignancies with poor prognosis worldwide. The treatment of breast cancer patients includes surgery, radiation, hormone therapy, chemotherapy, targeted drug therapy and immunotherapy. In recent years, immunotherapy has
Bi Lian, Xiaosong Chen, Kunwei Shen
doaj +1 more source
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
, 2016 Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S. +17 more
core +2 more sources